Geode Capital Management
IMDX

Geode Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Geode Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$860K Buy
262,053
+31,082
+13% +$180K ﹤0.01% 3405
2025
Q4 		$1.73M Buy
230,971
+32,518
+16% +$184K ﹤0.01% 3217
2025
Q3 		$659K Buy
198,453
+40,873
+26% +$115K ﹤0.01% 3523
2025
Q2 		$476K Sell
157,580
-1,327
-0.8% -$4.01K ﹤0.01% 3570
2025
Q1 		$486K Buy
158,907
+21,838
+16% +$59K ﹤0.01% 3557
2024
Q4 		$326K Buy
137,069
+33,089
+32% +$89.9K ﹤0.01% 3737
2024
Q3 		$296K Buy
103,980
+11,289
+12% +$35K ﹤0.01% 3771
2024
Q2 		$273K Buy
92,691
+30,258
+48% +$83.2K ﹤0.01% 3804
2024
Q1 		$183K Buy
62,433
+951
+2% +$2.94K ﹤0.01% 3971
2023
Q4 		$153K Hold
61,482
– – ﹤0.01% 4032
2023
Q3 		$202K Buy
61,482
+54
+0.1% +$201 ﹤0.01% 3976
2023
Q2 		$283K Buy
61,428
+11,805
+24% +$59.5K ﹤0.01% 3890
2023
Q1 		$352K Hold
49,623
– – ﹤0.01% 3787
2022
Q4 		$318K Sell
49,623
-125
-0.3% -$1.38K ﹤0.01% 3860
2022
Q3 		$726K Buy
49,748
+1,082
+2% +$18.7K ﹤0.01% 3546
2022
Q2 		$875K Sell
48,666
-14,656
-23% -$333K ﹤0.01% 3490
2022
Q1 		$1.89M Buy
63,322
+2,352
+4% +$75.2K ﹤0.01% 3286
2021
Q4 		$2.65M Buy
60,970
+3,128
+5% +$180K ﹤0.01% 3238
2021
Q3 		$4.12M Sell
57,842
-3,032
-5% -$279K ﹤0.01% 3023
2021
Q2 		$6.99M Buy
60,874
+3,820
+7% +$373K ﹤0.01% 2705
2021
Q1 		$5.92M Buy
57,054
+19,166
+51% +$1.82M ﹤0.01% 2704
2020
Q4 		$1.81M Buy
37,888
+8,472
+29% +$311K ﹤0.01% 3139
2020
Q3 		$817K Buy
29,416
+5,537
+23% +$159K ﹤0.01% 3282
2020
Q2 		$912K Buy
23,879
+7,511
+46% +$388K ﹤0.01% 3167
2020
Q1 		$802K Buy
16,368
+730
+5% +$35.8K ﹤0.01% 3099
2019
Q4 		$703K Buy
15,638
+353
+2% +$12.7K ﹤0.01% 3393
2019
Q3 		$641K Buy
15,285
+14
+0.1% +$550 ﹤0.01% 3392
2019
Q2 		$760K Buy
15,271
+6,410
+72% +$533K ﹤0.01% 3316
2019
Q1 		$699K Buy
8,861
+8,088
+1,046% +$522K ﹤0.01% 3303
2018
Q4 		$21K Hold
773
– – ﹤0.01% 4087
2018
Q3 		$38K Sell
773
-4
-0.5% -$206 ﹤0.01% 4050
2018
Q2 		$39K Sell
777
-416
-35% -$20.5K ﹤0.01% 3996
2018
Q1 		$50K Buy
1,193
+84
+8% +$5.55K ﹤0.01% 3951
2017
Q4 		$103K Buy
1,109
+8
+0.7% +$902 ﹤0.01% 3813
2017
Q3 		$166K Buy
1,101
+27
+3% +$2.83K ﹤0.01% 3711
2017
Q2 		$111K Buy
1,074
+326
+44% +$37.1K ﹤0.01% 3822
2017
Q1 		$89K Hold
748
– – ﹤0.01% 3847
2016
Q4 		$105K Hold
748
– – ﹤0.01% 3783
2016
Q3 		$75K Hold
748
– – ﹤0.01% 3865
2016
Q2 		$53K Sell
748
-139
-16% -$13K ﹤0.01% 3915
2016
Q1 		$81 Buy
+887
New +$78.6K ﹤0.01% 3884

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
FOR
Family Office Research Bethesda, Maryland $230M AUM 23.5% 1-Year Est. Return

Geode Capital Management's IMDX Position: Q1 2026 in Review

Geode Capital Management increased its Insight Molecular Diagnostics (IMDX) stake by 13% in Q1 2026, buying an estimated $180K and bringing the position to 262,053 shares worth $860K. The position accounts for ﹤0.01% of the portfolio, ranked #3405.

Geode Capital Management first reported a position in IMDX in Q1 2016 and has held it in 41 quarters since. The position peaked at $6.99M in Q2 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Geode Capital Management held 262,053 shares of Insight Molecular Diagnostics worth $860K as of Q1 2026.
  • Geode Capital Management bought 31,082 Insight Molecular Diagnostics shares in Q1 2026, an estimated $180K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3405 holding.
  • Geode Capital Management first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 41 quarters since.
  • Geode Capital Management's Insight Molecular Diagnostics position peaked at $6.99M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.